Dry Eye Syndrome Treatment Market Size, Share, Growth, Trends, and Global Industry Analysis: By  Product Type (Cyclosporine, Topical Corticosteroids, Artificial Tears, Punctal Plugs, Oral Omega Supplements, Others), By Dosage Form (Gels, Eye Solutions, Capsules & Tablets, Eye Drops, Ointments), By Prescription (Rx, OTC, Medical Device), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Eye Health Clinics, Others), and Region Forecast 2019-2030  

Dry Eye Syndrome Treatment Market size was valued at US$ 6,389.2 million in 2023 and is poised to grow at a CAGR of 9.5% from 2024-2030. Dry Eye Syndrome (DES) is a multifactorial disease of the ocular surface characterized by a loss of homeostasis of the tear film. The global market is experiencing robust growth driven by an aging population, increasing screen time, environmental factors, and growing awareness about eye health. The market is primarily fueled by the rising prevalence of dry eye syndrome, estimated to affect 5-50% of the global population, depending on the definition used and the population studied. The growing adoption of digital devices, leading to increased screen time and reduced blink rates, is contributing significantly to the rise in dry eye syndrome cases.

Additionally, the surge in LASIK and cataract surgeries, which often result in temporary or chronic dry eye, is boosting the demand for treatments. Recent developments in drug delivery systems, including nanotechnology-based formulations and sustained-release devices, have reshaped the treatment landscape. The market is witnessing a shift towards more targeted therapies addressing the underlying causes of dry eye syndrome, rather than just symptom management. However, the market faces challenges such as the high cost of advanced treatments, potential side effects of long-term medication use, and the need for more accurate diagnostic tools. Despite these challenges, the market is expected to continue its growth trajectory, driven by the persistent demand for effective treatments and the expanding elderly population. Moreover, government agencies and eye health organizations have been actively involved in raising awareness about dry eye syndrome and promoting regular eye check-ups, further driving the demand for treatments. For instance, the National Eye Institute (NEI) in the United States provides extensive resources on dry eye and supports research into new treatments.

Key Developments

• In 2021, the USA Food and Drug Administration (FDA) approved one of the dry eye products, Tyrvaya nasal spray. This spray simulates tear, oil, and mucin production, which eliminates burning sensations.
• In January 2017, Novaliq announced the positive top-line results of phase 2 clinical trial evaluating CyclASol in adults with moderate to severe dry eye disease.
• In June 2015, Allergan plc, a pharmaceutical company acquired Oculeve Inc, a medical device company that focuses on new technologies for dry eye disease to improve market position in the market.
• In July 2013, Novaliq GmbH won European approval for its lubricating, drug-delivering eye drop NovaTears, designed for over-the-counter treatment of dry eye syndrome.